113 related articles for article (PubMed ID: 15217959)
1. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Gandara DR; West H; Chansky K; Davies AM; Lau DH; Crowley J; Gumerlock PH; Hirsch FR; Franklin WA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4205s-4209s. PubMed ID: 15217959
[TBL] [Abstract][Full Text] [Related]
2. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
West HL; Franklin WA; McCoy J; Gumerlock PH; Vance R; Lau DH; Chansky K; Crowley JJ; Gandara DR
J Clin Oncol; 2006 Apr; 24(12):1807-13. PubMed ID: 16622257
[TBL] [Abstract][Full Text] [Related]
4. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
Miller VA; Hirsch FR; Johnson DH
J Clin Oncol; 2005 May; 23(14):3288-93. PubMed ID: 15886316
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
11. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Kris MG; Giaccone G; Davies A; Fukuoka M; Garfield DH; Jassem J; Quoix EA; Sandler AB; Scagliotti GV; Van Meerbeeck JP; West H
J Thorac Oncol; 2006 Nov; 1(9 Suppl):S32-6. PubMed ID: 17409999
[TBL] [Abstract][Full Text] [Related]
14. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Yano S; Kanematsu T; Miki T; Aono Y; Azuma M; Yamamoto A; Uehara H; Sone S
Cancer Sci; 2003 May; 94(5):453-8. PubMed ID: 12824893
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
16. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Milton DT; Kris MG; Gomez JE; Feinstein MB
Support Care Cancer; 2005 Jan; 13(1):70-2. PubMed ID: 15558327
[TBL] [Abstract][Full Text] [Related]
17. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Patel JD
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S43-7. PubMed ID: 15638957
[TBL] [Abstract][Full Text] [Related]
18. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
Jackman DM; Chirieac LR; Jänne PA
Semin Respir Crit Care Med; 2005 Jun; 26(3):342-52. PubMed ID: 16052436
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
